Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • Waystar has entered a definitive agreement to acquire Iodine Software for a total enterprise value of USD 1.25 billion.
  • The deal is expected to expand Waystar’s total addressable market by more than 15 percent.
  • The acquisition adds recurring subscription-based revenue and is projected to be accretive to margins and non-GAAP net income by 2027.

Waystar has announced a definitive agreement to acquire Iodine Software for a total enterprise value of USD 1.25 billion. The transaction is set to advance Waystar’s position in healthcare payment software by integrating Iodine’s proprietary clinical intelligence platform.

Waystar provides cloud-based healthcare payment software serving more than one million providers. Iodine Software, backed by Advent International, is known for its AI-powered clinical intelligence used by leading U.S. health systems. The two companies will combine their capabilities to target administrative inefficiencies, especially claim denials, that cost healthcare providers billions annually.

Waystar expects the acquisition to be immediately accretive to gross and adjusted EBITDA margins. Revenue growth and non-GAAP net income per diluted share are also projected to benefit, beginning in 2027. The transaction includes a 50/50 mix of cash and stock, with Iodine shareholders retaining an estimated 8 percent stake in the combined entity. Advent, Iodine’s largest shareholder, will receive only Waystar shares and be subject to an 18-month lock-up.

Strategically, the transaction enhances Waystar’s AltitudeAI™ platform through integration with Iodine’s clinical AI engine, IodineIQ, which processes billions of clinical data points from over one-third of U.S. inpatient discharges. Waystar anticipates this integration will accelerate development in key areas like prior authorizations, claims management, and appeals automation.

The acquisition is also expected to strengthen client relationships. Iodine currently supports a wide network of top hospitals, and the combined platform is expected to serve 17 of the 20 U.S. News Best Hospitals.

Waystar has identified over USD 15 million in run-rate cost synergies, targeted within 18 to 24 months of closing. Post-transaction, the company projects a net leverage ratio of approximately 3.5x.

The transaction is expected to close by the end of 2025, pending regulatory approvals and customary conditions. A conference call related to the transaction was scheduled for July 23, 2025.

Preliminary second quarter 2025 results from Waystar indicate estimated revenue of USD 271 million, up approximately 15 percent from the prior year. These figures remain unaudited ahead of the full quarterly report due on July 30, 2025.